Results 21 to 30 of about 8,117 (271)
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy [PDF]
, 2023 Background: The phase IIIb, randomized, parallel-group, placebo-controlled ANDHI double-blind (DB) study extended understanding of the efficacy of benralizumab for patients with severe eosinophilic asthma.Adlington, Timothy, Bardelas, Jose, Beck, Ekkehard, Beghé, Bianca, Berger, William, Bjerrum, Anne Sofie, Blanc, François-Xavier, Blasi, Francesco, Bobolea, Irina Diana, Bonnet, Reiner, Bonniaud, Philippe, Bourdin, Arnaud, Brehler, Randolf, Burden, Annie, Calhoun, William, Campbell, Edward, Canonica, Giorgio Walter, Caruso, Cristiano, Chanez, Pascal, Chapman, Kenneth, Chaudhuri, Rekha, Cheema, Amarjit, Cherry, William Brett, Chupp, Geoffrey, Clore, Lee, Cole, Jeremy, Conemans, Lennart, Corsico, Angelo Guido, Cosio, Borja, Crimi, Nunzio, Curiac, Dan, Darveaux, Jared, Davis, Benjamin, de la Cruz, Luis, de Luiz Martinez, Gustavo, de Luiz, Gustavo, Deleon, Samuel, Deschampheleire, Maud, Deslee, Gaetan, Devouassoux, Gilles, Didier, Alain, Doberer, Daniel, Dorscheid, Delbert, Douadi, Youcef, Echave-Sustaeta, Jose Maria, Fakih, Faisal, Fernandez, Ana Gomez-Bastero, Fost, David, Fry, Stephanie, Gall, Xavier Muñoz, Garcia Gil, Esther, Garcia Rivero, Juan Luis, Garcia, Ismael Ali, Girodet, Pierre-Olivier, Gleiber, Wolfgang, Gonzalez Perez, Ruperto, Gonzalez, Erika, Goodman, Brad, Goss, Deborah, Guarnieri, Gabriella, Guerrero, Raquel Morillo, Hajal, Rizan, Harris, James, Harrison, Tim, Heidarian Raissy, Hengameh, Henriquez Santa, Aythamy, Hilberg, Ole, Hill, David, Himpe, Ulrike, Holguin, Fernando, Holters, Jurgen, Hussain, Iftikhar, Ilowite, Jonathan, Jarratt, Mikell, Kao, Neil, Kashyap, Ravindra, Kaufman, David, Keeling, Nanna, Kilpeläinen, Maritta, Kronsbein, Juliane, Kureishy, Shahrukh, Kwiatek, Justin, Lacedonia, Donato, Langeveld, Bas, Larivee, Pierre, Leflein, Jeffrey, Lehmann, Sverre, Leong, Mila, Leuppi, Joerg, Lin, Robert, Louis, Renaud, Lugogo, Njira, Mahay, Guillaume, Mansur, Adel, Marcus, Michael, Marshall, Gailen, Martinot, Jean Benoit, Maselli Caceres, Diego Jose, Mehta, Hemalini, Mehta, Vinay, Melloni, Boris, Menzella, Francesco, Micheletto, Claudio, Milanese, Manlio, Millard, Mark, Milstone, Aaron, Moore, Wendy, Moss, Mark, Mozo, Paloma Campo, Mumneh, Nayla, Nasser, Shuaib, Nocent Ejnaini, Cecilia, Nordstrom, Monica, Olivenstein, Ronald, Palumbo, Michael, Pan, Carmen Vidal, Papi, Alberto, Peche, Rudi, Pelaia, Girolamo, Peveri, Silvia, Pfeffer, Paul, Philteos, George, Pini, Laura, Pison, Christophe, Pleskow, Warren, Pohl, Wolfgang, Poirier, Claude, Pradelli, Johana, Prenner, Bruce, Puppala, Dileep, Ramos Gonzalez, Jacinto, Ramsey, Clare, Randolph, Christopher, Reibman, Joan, Ribas, Christian Domingo, Rivera, Carlos Martinez, Robinette, Emory, Rodicio, Ileana, Rodriguez Hermosa, Juan Luis, Rolf, Jeffrey, Roux, Pauline-Marie, Santus, Pierachille, Saralaya, Dinesh, Schaum, Thomas, Schmid-Grendelmeier, Peter, Schreiber, Jens, Schuette, Wolfgang, Schulz, Christian, Scichilone, Nicola, Senna, Gianenrico, Short, Philip, Sikand, Vinay, Skowasch, Dirk, Smit, Arthur, Soong, Weily, Soto Campos, Jose Gregorio, Spadaro, Giuseppe, St. John, Roy, Staaks, Gerald, Stenfors, Nikolai, Steven, Gary, Subramaniam, Vijay, Sumino, Kaharu, Sussman, Robert, Sztejman, Eric, Taillé, Camille, Tan, Ricardo, Tanus, Tonny, Taube, Christian, Tellez, Sergio Campos, Tiotiu, Iuliana-Angelica, Titlestad, Ingrid, Tunsäter, Alf, van Veen, Helena, Vinge, Ines, von Garnier, Christophe, Walker, Brandie, Welte, Tobias, Wenzel, Sally, Willem van den Berg, Jan, Zafra, Heidi +180 morecore +3 more sourcesDurability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study [PDF]
Frontiers in AllergyIntroductionSevere eosinophilic asthma (SEA) often co-occurs with chronic rhinosinusitis with nasal polyps (CRSwNP), worsening asthma symptoms. Earlier studies have shown that benralizumab improves asthma outcomes with greater efficacy if patients ...Luisa Brussino, Maria Aliani, Elena Altieri, Pietro Bracciale, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Giorgio Walter Canonica, Cristiano Caruso, Cristiano Caruso, Stefano Centanni, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Laura Malerba, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Jan Walter Schroeder, Gianenrico Senna, Alessandra Vultaggio, Maria D’Amato +24 moredoaj +2 more sourcesBenralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long‐term safety (TATE study)
Pediatric Allergy and ImmunologyBenralizumab is an anti‐interleukin‐5 receptor α monoclonal antibody approved as an add‐on maintenance treatment for patients with uncontrolled severe asthma.H. Wedner, Takao Fujisawa, T. Guilbert, Masanori Ikeda, Vinay Mehta, Jonathan S. Tam, Pradeep B. Lukka, S. Asimus, T. Durżyński, J. Johnston, Wendy I. White, Mihir Shah, V. Werkström, M. Jison +13 moresemanticscholar +2 more sourcesEffect of benralizumab on histopathology and inflammatory signatures in a clinical cohort of eosinophilic esophagitis. [PDF]
Dis EsophagusSummary A preliminary report from the recent phase 3 trial of benralizumab, a monoclonal antibody that binds to interleukin-5 receptor alpha (IL5Rα), in patients with EoE revealed that medication use led to tissue eosinophil eradication but did not meet ...Pyne AL, Uchida AM, Hazel MW, Stubben CJ, Chang JW, Bailey DD, Gonsalves N, Allen-Brady K, Peterson KA, Pletneva MA. +9 moreeuropepmc +2 more sourcesMepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis [PDF]
Frontiers in MedicineIntroduction Asthma associated with eosinophilic granulomatosis with polyangiitis (EGPA) is often severe and corticosteroid-dependent, leading to significant morbidity.C. Desaintjean, K. Ahmad, J. Traclet, Mathieu Gerfaud-Valentin, C. Durel, J. Glérant, Arnaud Hot, F. Lestelle, Sabine Mainbourg, M. Nasser, P. Sève, S. Turquier, Gilles Devouassoux, V. Cottin +13 moresemanticscholar +2 more sourcesThe effects of benralizumab on lung volumes and airway resistance in severe eosinophilic asthma: a real-world study [PDF]
CureusIntroduction: Add-on biological monoclonal antibodies such as benralizumab (anti-IL-5Ra) are recommended by international guidelines to reduce exacerbations in severe eosinophilic asthma (SEA).Alves, Carolina da Silva, Duarte-Ramos, Filipa, Gerardo, António Madeira, Gomes, Margarida, Liberato, Hedi, Lopes, Carlos, Mendes, Ana, Pardal, Cecília, Sokolova, Anna, Tonin, Fernanda +9 morecore +2 more sourcesBenralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study
Journal of Asthma and AllergyPurpose Real-world evidence of benralizumab effectiveness on nasal polyps (NP) and asthma outcomes in patients with severe eosinophilic asthma (SEA) and comorbid chronic rhinosinusitis with NP are limited. The objective of this study was to assess NP and Tham T. Le, B. Emmanuel, R. Katial, Trung N. Tran, J. Kwiatek, D. Cohen, Shoshana Daniel, Yunhui Cao, Vivian H Shih, Maria Melcón, G. Devouassoux, G. Pelaia +11 moresemanticscholar +3 more sourcesPharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial [PDF]
British Journal of Clinical PharmacologyBenralizumab, a humanized, afucosylated monoclonal antibody against the interleukin 5 receptor, α subunit, causes rapid depletion of eosinophils by antibody‐dependent cellular cytotoxicity.Claire Emson, Joseph K. Han, C. Hopkins, S. Asimus, Jennifer A Cann, David Chain, Yuling Wu, Yasa Reddy, C. Mccrae, David Cohen, James L Kreindler, V. Werkström, M. Jison, M. Wagenmann, C. Bachert +14 moresemanticscholar +2 more sourcesEffect of benralizumab treatment on the airway microbiome in COPD [PDF]
ERJ Open ResearchBackground
One-third of patients with COPD have an eosinophilic inflammatory phenotype. Benralizumab is an afucosylated humanised monoclonal antibody that targets the interleukin-5 receptor α subunit, leading to rapid and near-complete eosinophil ...Koirobi Haldar, Vijay Mistry, Mathew Richardson, Corinne Hamblet, Maria Jison, Michael R. Barer, Christopher McCrae, Christopher E. Brightling +7 moredoaj +2 more sources
